GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SynAct Pharma AB (OSTO:SYNACT) » Definitions » EPS (Diluted)

SynAct Pharma AB (OSTO:SYNACT) EPS (Diluted) : kr-6.64 (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is SynAct Pharma AB EPS (Diluted)?

SynAct Pharma AB's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was kr-2.68. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was kr-6.64.

SynAct Pharma AB's EPS (Basic) for the three months ended in Dec. 2023 was kr-2.68. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was kr-6.64.

SynAct Pharma AB's EPS without NRI for the three months ended in Dec. 2023 was kr-2.68. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was kr-6.64.

During the past 3 years, the average EPS without NRIGrowth Rate was -78.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was -33.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 8 years, SynAct Pharma AB's highest 3-Year average EPS without NRI Growth Rate was 1.60% per year. The lowest was -78.90% per year. And the median was -23.70% per year.


SynAct Pharma AB EPS (Diluted) Historical Data

The historical data trend for SynAct Pharma AB's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SynAct Pharma AB EPS (Diluted) Chart

SynAct Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial -1.62 -1.18 -2.68 -3.60 -6.64

SynAct Pharma AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.08 -1.59 -1.37 -1.00 -2.68

Competitive Comparison of SynAct Pharma AB's EPS (Diluted)

For the Biotechnology subindustry, SynAct Pharma AB's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SynAct Pharma AB's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SynAct Pharma AB's PE Ratio distribution charts can be found below:

* The bar in red indicates where SynAct Pharma AB's PE Ratio falls into.



SynAct Pharma AB EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

SynAct Pharma AB's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-215.81-0)/32.524
=-6.64

SynAct Pharma AB's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-90.543-0)/35.109
=-2.58

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-6.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SynAct Pharma AB  (OSTO:SYNACT) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


SynAct Pharma AB EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of SynAct Pharma AB's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


SynAct Pharma AB (OSTO:SYNACT) Business Description

Traded in Other Exchanges
Address
Sheelevagen 2, Lund, SWE, 223 81
SynAct Pharma AB is a clinical-stage biotech company focused on resolving inflammation through selective activation of the melanocortin system. The company has a platform technology based on a new class of drug candidates that target acute exacerbations in chronic inflammatory diseases with the primary aim of stimulating natural healing mechanisms. AP1189, the company's lead drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.

SynAct Pharma AB (OSTO:SYNACT) Headlines

No Headlines